» Articles » PMID: 37064038

Prior Treated Tuberculosis and Mortality Risk in Lung Cancer

Overview
Specialty General Medicine
Date 2023 Apr 17
PMID 37064038
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lung cancer is one of the leading causes of cancer death worldwide, and tuberculosis (TB) is a common pre-existing disease. However, there is scarce literature studying the mortality risk in patients with prior TB and subsequent lung cancer.

Methods: We recruited lung cancer patients from the Taiwan Cancer Registry from 2011 to 2015 and classified them into two groups according to presence or absence of prior TB. We then matched them in a ratio of 1:4 using the exact matching approach. The mortality risk within 3 years after diagnosis of lung cancer was analyzed and compared between these two groups.

Results: During the study period, 43,472 patients with lung cancer were recruited, and of these, 1,211 (2.79%) patients had prior TB. After matching, this cohort included 5,935 patients with lung cancer in two groups: patients with prior TB before lung cancer ( = 1,187) and those without ( = 4,748). After controlling for demographic factors and comorbidities, the patients with prior TB had increased adjusted hazard ratios of 1.13 (95% CI: 1.04-1.23) and 1.11 (1.02-1.21) for all-cause and cancer-specific 3-year mortality, respectively, compared to the lung cancer patients without prior TB. Duration between TB and lung cancer (<1 year vs. 1-3 years vs. >3 years) had no differences for mortality risk.

Conclusion: In the present study, 2.79% patients with lung cancer had prior TB, which was associated with higher 3-year mortality after they developed lung cancer. The mortality risk with prior TB did not decrease even if >3 years passed before diagnosis of lung cancer.

Citing Articles

Genetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.

Mahjabeen A, Hasan M, Rahman M, Islam M, Khan R, Kaiser M PLoS One. 2024; 19(10):e0312072.

PMID: 39432502 PMC: 11493268. DOI: 10.1371/journal.pone.0312072.


The Factors Associated With Mutant Epidermal Growth Factor Receptor Positivity in Patients With Lung Cancer: A Study From a Tertiary Care Center in Pakistan.

Mahmud T, Idrees M, Rafique S, Abbas R, Anwar I, Saqib M Cureus. 2024; 16(9):e69631.

PMID: 39429333 PMC: 11487466. DOI: 10.7759/cureus.69631.


Tuberculous Pleural Effusion-Derived Exosomal miR-130b-3p and miR-423-5p Promote the Proliferation of Lung Cancer Cells via Cyclin D1.

Kang H, Yun S, Shin S, Youn D, Son G, Lee J Int J Mol Sci. 2024; 25(18).

PMID: 39337604 PMC: 11431986. DOI: 10.3390/ijms251810119.


Dark under the Lamp: Neglected Biological Pollutants in the Environment Are Closely Linked to Lung Cancer.

Wang D, Chan B, Zhang B, Wong K, Kan L, Wong C Int J Mol Sci. 2024; 25(6).

PMID: 38542056 PMC: 10970385. DOI: 10.3390/ijms25063081.

References
1.
Dai J, Yang P, Cox A, Jiang G . Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective. Oncotarget. 2017; 8(11):18513-18524. PMC: 5392346. DOI: 10.18632/oncotarget.14505. View

2.
Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl K . Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med. 2010; 207(7):1409-20. PMC: 2901066. DOI: 10.1084/jem.20091885. View

3.
Lee S, Lee J, Park Y, Lee C, Lee S, Yim J . Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer. J Thorac Oncol. 2014; 9(6):812-7. DOI: 10.1097/JTO.0000000000000158. View

4.
Mosser D, Edwards J . Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-69. PMC: 2724991. DOI: 10.1038/nri2448. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View